Shaanxi Micot Technology Co., Ltd. is a privately-owned enterprise based in China that specializes in researching, developing, and producing pharmaceutical products for the treatment of cardiovascular, metabolic, and liver diseases.
Clinical Trials associated with Shaanxi Mycotech Pharmaceutical Technology Co., Ltd.
NCT07122401
/ RecruitingPhase 3
A Multicenter, Randomized, Double-blind, Double-dummy, Phase III Study to Evaluate the Efficacy and Safety of MT1013 Versus Cinacalcet as Active Control in Secondary Hyperparathyroidism Patients on Maintenance Dialysis
MT1013 is a first-in-class dual-target agonist. This study is a multicenter, randomized, double-blind, double-dummy phase III clinical study being conducetd to evaluate the efficacy and safety of MT1013 compared with active control cinacalcet in secondary hyperparathyroidism patients on maintenance dialysis. Subjects will be 1:1 randomized to receive MT1013 or cinacalcet for 26 weeks. Evaluations of iPTH, Ca, P, BMD, and biomarkers will be done across the study period, to compare efficacy and safety of MT1013 to cinacalcet.
A Single-center, Randomized, Double-blind, Placebo-controlled Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Dose (SAD) Administration of MT1011 Injection in Healthy Subjects
This is a single-center, randomized,double-blind, placebo-controlled Phase I study to evaluate safety, PK and PD of single ascending dose (SAD) of MT1011 injection in healthy adult subjects. Includes 5 dose cohorts, with 40 subjects planned for enrollment.
[Translation] A randomized, double-blind, placebo-controlled Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending dose (SAD) and multiple ascending dose (MAD) administration of XTL6001 for injection in healthy and obese subjects
评价注射用XTL6001在健康和肥胖成年受试者中的安全性和耐受性
[Translation]
To evaluate the safety and tolerability of XTL6001 for injection in healthy and obese adult subjects
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.